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Summary
Quality of life is increasingly recognized as an important secondary endpoint of hematopoietic cell 
transplantation (HCT). The current study examined the extent to which attrition results in biased 
estimates of patient quality of life. The study also examined whether patients differ in terms of 
trajectories of quality of life in the first six months post-transplant. A secondary data analysis was 
conducted of 701 participants who enrolled in the Blood and Marrow Transplantation Clinical 
Trials Network (BMT CTN) 0902 trial. Participants completed the SF-36, a measure of quality of 
life, prior to transplant and 100 and 180 days post-transplant. Results indicated that attrition 
resulted in slightly biased overestimates of quality of life but the amount of overestimation 
remained stable over time. Patients could be grouped into three distinct classes based on physical 
quality of life: 1) low and stable; 2) average and declining, then stable; and 3) average and stable. 
Four classes of patients emerged for mental quality of life: 1) low and stable; 2) average, 
improving, then stable; 3) higher than average (by almost 1 SD) and stable; and 4) average and 
stable. Taken together, these data provide a more comprehensive understanding of quality of life 
that can be used to educate HCT recipients and their caregivers.
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Advances in hematopoietic cell transplant (HCT) have resulted in its increasing use in recent 
years, giving rise to a growing number of HCT survivors (Majhail, et al 2013, Pasquini and 
Wang 2011). Nevertheless, HCT remains a physically and emotionally arduous process; 
patients often suffer from short- and long-term morbidity and deficits in quality of life. 
Awareness of the importance of quality of life to adult HCT recipients is reflected in a 
growing body of literature on the topic. Although findings are heterogeneous, in general 
evidence suggests that patients’ quality of life is impaired relative to population norms 
before HCT, nadirs within the first 100 days post-transplant, and then demonstrates some 
recovery in the years thereafter (Grulke, et al 2012, Pidala, et al 2009, Pidala, et al 2010). 
Nevertheless, long-term quality of life remains impaired relative to population norms 
(Pidala, et al 2009, Pidala, et al 2010). The domains of quality of life that tend to be most 
compromised are general health [.7 SD lower than population norms(Andrykowski, et al 
2005)], social functioning [.4–.6 SD lower (Andrykowski, et al 2005, Kopp, et al 2005)], 
role functioning [.4 SD lower (Kopp, et al 2005)], and physical functioning [.3–.5 SD lower 
(Andrykowski, et al 2005, Kopp, et al 2005)].
While many studies have described quality of life among adult HCT recipients, 
methodological limitations have prevented widespread use of these findings for clinical 
education and intervention. For example, study attrition due to morbidity and mortality 
range from 29–65% in the first year after HCT (Bevans, et al 2006, Broers, et al 2000, 
Hjermstad, et al 1999b, Lee, et al 2001, McQuellon, et al 1998, Syrjala, et al 2004) and 
patients with better quality of life are more likely to have complete data (Altmaier, et al 
2006, Bevans, et al 2006, Broers, et al 2000, Bush, et al 2000, Syrjala, et al 2004). Attrition 
has not been statistically addressed in most previous research, leading to potentially biased 
overestimates of patient quality of life. In addition, quality of life has been almost 
exclusively described through the use of sample means and standard deviations, which may 
obscure classes of patients with distinct trajectories of quality of life over time (e.g., patients 
with early versus late effects).
The current study addressed methodological limitations in existing research by examining 
change in quality of life in a large sample of HCT patients recruited as part of the Blood and 
Marrow Transplant Clinical Trials Network (BMT CTN) 0902 protocol. The aims of this 
secondary analysis were threefold. The first aim was to model the mean trajectory of QOL 
during the first six months after HCT, controlling for attrition. Based on previous research 
(Pidala, et al 2009, Pidala, et al 2010), we hypothesized that QOL would improve on average 
over time. The second aim was to determine whether HCT patients can be categorized into 
distinct classes based on their QOL trajectory. We expected that at least two classes of 
patients could be identified who differ in their experience of quality of life following HCT 
(e.g., patients with early versus late effects). The third aim was to examine whether classes 
differed on the basis of baseline sociodemographic and clinical characteristics. Based on 
previous literature (Andrykowski, et al 1995, Diez-Campelo, et al 2004, Heinonen, et al 
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2001, Hjermstad, et al 1999a, Syrjala, et al 1993), we hypothesized that age, gender, race, 
ethnicity, marital status, education, income, baseline Karnofsky score, pre-HCT 
comorbidities, transplant type, myeloablative preparative regimen among allogeneic 
recipients, and length of hospital stay would predict class membership.
Materials and Methods
Participants
Participants were recruited as part of a larger, multicenter randomized controlled trial (RCT) 
of stress management and exercise among HCT patients (BMT CTN 0902) (Jacobsen, et al 
2014). Eligibility criteria were that patients be: a) 18 years of age or older, b) able to speak 
and read English, c) able to exercise at low to moderate intensity as determined by physician 
judgment and self-reported ability to walk up one flight of stairs without supplementary 
oxygen, d) willing and able to provide informed consent, e) willing to comply with study 
procedures and reporting requirements, and f) planning to undergo autologous or allogeneic 
transplant within six weeks. Patients were excluded if they: a) had orthopedic, neurologic, or 
other problems which prevented safe ambulation and protocol adherence, b) were 
participating in another clinical trial with quality of life or functional status as a primary 
endpoint, c) were planning to receive anti-cytotoxic therapies other than tyrosine kinase 
inhibitors, d) were planning to receive donor lymphocyte infusion within 100 days of 
transplant, e) were planning to receive tandem transplant (i.e., planned autologous/
autologous or autologous/allogeneic HCT).
Procedure
Eligibility was determined via chart review and in consultation with the attending physician. 
Eligible patients were recruited and informed consent was obtained prior to the day of graft 
infusion (i.e., day 0). Following informed consent, participants completed a baseline 
assessment and were randomized to receive audiovisual materials on exercise, stress 
management, both, or usual care as part of the larger RCT (Jacobsen, et al 2014). The trial 
was registered with clinical trials.gov (NCT01278927). In addition to the pre-HCT baseline 
assessment, participants completed follow-up assessments of quality of life at 100 days and 
180 days post-HCT. Participants were recruited between January 2011 and June 2012.
Measures
Demographic and clinical data—Demographic data obtained prior to HCT included 
age, gender, race, ethnicity, marital status, education, and income. Co-morbid medical 
conditions were measured using the Hematopoietic Cell Transplant – Comorbidities Index 
(HCT-CI) (Sorror, et al 2005). Clinical data were collected via BMT CTN reporting and 
included pre-HCT Karnofsky score, disease type, transplant type, myeloablative preparative 
regimen among allogeneic recipients, and length of hospital stay.
Quality of life—The acute (one week) version of Medical Outcomes Study Short Form, a 
36-item questionnaire, was used to assess health-related quality of life (SF-36) (Ware, et al 
1993). The SF-36 is composed of eight subscales: Physical Functioning, Role Physical, 
Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental 
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Health. Scores on these subscales range from 0 to 100 with higher scores reflecting better 
quality of life. Weighted averages of these eight subscales are used to calculate two 
summary scores: the Physical Component Summary (PCS) and Mental Component 
Summary (MCS) (Ware, et al 1994). Component summary scores are expressed as T scores 
which have been standardized using U.S. population norms.
Statistical Analyses
Change in MCS and PCS, independently, were initially evaluated using mixed models with a 
focus on linear and quadratic trends among all participants across the pre-transplant, 100-
day, and 180-day measures. The final model selected for both PCS and MCS had a linear 
random effect and a quadratic fixed effect. Attrition was included as a fixed effect in some 
tested versions (coded as 0 or 1 for participants who completed a Time 3 assessment versus 
did not, respectively), but was not found to interact with the linear and quadratic trends and 
was not included in the final model.
To examine trajectories of quality of life, growth mixture modeling (GMM) (Muthén 2004, 
Ram and Grimm 2009) was used. Adapted from random effects modeling, GMM is able to 
determine not only whether a group of persons changes on some outcome measure but also 
whether there are individual differences in the rates of change among group members 
(Nesselroade and Baltes 1979). Stated differently, GMM evaluates whether there are classes 
of individuals who differ in terms of their initial starting points and/or rates of change over 
time. GMM was conducted separately for PCS and MCS. Because change was the outcome 
of interest, participants were included in GMM analyses if they had completed a baseline 
assessment and at least one follow-up assessment. Due to the large number of participants 
required for such analyses, participants were included regardless of transplant type. 
Beginning with a 1-class model, additional models with incrementally more classes were 
compared using fit indices and other criteria (e.g., minimal class size of 25) to determine the 
optimal number of classes for each measure.
Differences in class membership were examined as a function of demographic factors (i.e., 
age, gender, race, ethnicity, marital status, education, income) and clinical factors (i.e., 
baseline Karnofsky score, pre-HCT comorbidities, transplant type, myeloablative 
preparative regimen among allogeneic recipients, length of hospital stay) using correlations 
and chi-square analyses. Length of hospital stay was conceptualized as a proxy for 
complications in the acute post-transplant period. PCS and MCS class membership were the 
outcome measures. GMM was conducted using Mplus v. 7 (Muthén and Muthén 1998–
2010), all other analyses were conducted using SAS 9.4 (SAS Institute 2002–2003).
Results
Participant characteristics are provided in Table 1. The majority of participants were male, 
non-Hispanic, white, married, had graduated from college, and reported an annual household 
income of less than $75,000 per year. Participants were on average 54 years of age (range 
18–75). The most frequent diagnosis was myeloma (27%) and 50% of the sample received 
an autologous transplant. A total of 219 (31%) of participants did not complete the Time 3 
assessment. Patients not completing the study were more likely to report lower annual 
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household income (p=.006), have more pre-HCT comorbidities (p=.002), and to have 
received allogeneic HCT (p=.001). No differences were found between patients who did and 
did not complete the study on gender, age, race/ethnicity, education, marital status, 
employment status, pre-HCT Karnofsky score, number of days hospitalized in the first 100 
days post-HCT, baseline PCS, or baseline MCS (p values >.05). As published previously 
(Jacobsen, et al 2014), study arms in the larger randomized trial did not demonstrate 
statistically significant differences on baseline sociodemographic, clinical, or quality of life 
variables and the intervention did not impact quality of life (Jacobsen, et al 2014); therefore, 
the study arms were collapsed for the current analyses.
Figure 1 shows mean level changes in study participants over time by study completion 
status. Time 3 scores for non-completers were estimated based on scores at previous time 
points and linear and quadratic slopes among completers. Mixed models analysis examining 
change in PCS indicated significant linear (B=−.67, p=.002) and quadratic (B=.11, p=.001) 
effects of time controlling for attrition (B=−2.17, p=.005), indicating that PCS scores on 
average declined slightly from pre-HCT to day 100, then improved from day 100 to day 180 
post-HCT. PCS scores were significantly lower at all assessments for patients who did not 
complete the study but rate of change in PCS was similar between groups. Mixed models 
analysis examining change in MCS indicated a significant linear effect of time (B=.61, p=.
02) but not a quadratic effect (B=−.07, p=.11) controlling for attrition (B=−1.58, p=.04), 
indicating that MCS scores improved on average over the study period. MCS scores were 
significantly lower at all assessments for patients who did not complete the study but rate of 
change in MCS was similar between groups. Mixed models analyses controlling for study 
arm yielded similar results.
A total of 572 participants completed the baseline assessment and at least one follow-up and 
were therefore included in GMM analyses. Because mixed models analyses with and 
without inclusion of attrition as a control variable yielded similar patterns of results, attrition 
was not controlled in GMM analyses. Based on changes in PCS scores, study participants 
could be grouped into three distinct classes. As shown in Figure 2A, members of class 1 
(n=437) reported poor physical quality of life at baseline (approximately one SD below 
population norms) and their physical quality of life remained poor across time. Members of 
class 2 (n=30) reported physical quality of life comparable to population norms at baseline 
and demonstrated significant declines in quality of life at 90 days post-HCT (i.e., 
approximately 1.5 SD below population norms) which remained stable at 180 days post-
HCT. Members of class 3 (n=105) reported physical quality of life which was comparable to 
population norms at baseline and across time. Members of class 1 (i.e., poor and stable 
physical quality of life) tended to be younger than class 3 (p<.05), had greater pre-HCT 
comorbidities than class 3 (p<.05), and were more likely to have received myeloablative 
allogeneic HCT than class 3 (p=.01). Members of class 2 (i.e., declining physical quality of 
life) were more likely to have received allogeneic HCT than classes 1 and 3 (p=.0002), were 
hospitalized more days in the first 100 days than classes 1 and 3 (p values<.05), and reported 
lower income than members of classes 1 and 3 (p=.0024). Members of class 3 (i.e., average 
and stable physical quality of life) were more likely to be working pre-HCT than class 1 (p<.
0001) and class 2 (p=.004) and reported greater income than class 1 (p=.0008) and class 2 
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(p=.02). There were no class differences in physical quality of life by gender, race, ethnicity, 
education, marital status, or pre-HCT Karnofsky scores (p values>.32)
Participants could be grouped into four distinct classes based on changes in their MCS 
scores. As shown in Figure 2B, members of class 1 (n=93) reported poor mental quality of 
life at baseline (i.e., approximately 1 SD below population norms) which remained stable 
across time. Members of class 2 (n=52) reported mental quality of life at baseline that was 
comparable to population norms which improved at 90 days post-HCT (i.e., one SD above 
population norms) and remained stable thereafter. Members of class 3 (n=193) reported 
good baseline mental quality of life (i.e., approximately 1 SD above population norms), 
which remained consistently high thereafter. Members of class 4 (n=234) reported baseline 
mental quality of life comparable to population norms which remained stable over time. 
Members of class 1 (i.e., poor and stable mental quality of life) were younger on average 
than the other classes (p<.0001), more likely to be female than classes 3 (p=.03) and 4 (p=.
006), reported lower income than classes 2 and 3 (p=.001), had greater pre-HCT 
comorbidities than classes 3 and 4 (p values<.05), and less likely to be married than the 
other classes (p values≤.02). Members of class 3 (i.e., good and stable mental quality of life) 
were more likely to be working pre-HCT compared to class 1 (p=.0009) and class 4 (p=.
006). There were no class differences in mental quality of life by race, ethnicity, education, 
pre-HCT Karnofsky scores, transplant type, myeloablative preparatory regimen among 
allogeneic recipients, or length of hospital stay (p values>.14).
Conclusions
The current study examined change in physical and mental quality of life over time in a 
large sample of HCT recipients. The first goal of the study was to examine the effects of 
attrition on estimates of quality of life. Although patients who did not complete the study 
demonstrated lower physical and mental quality of life at each assessment than those who 
did, physical and mental quality of life changed similarly over time for both groups. While 
group differences were significant, they were not large (i.e., approximately .2 standard 
deviations). These data suggest that longitudinal quality of life analyses that do not control 
for attrition in HCT recipients are likely slight overestimates and the amount of 
overestimation is consistent across time.
The second goal of the study was to examine between-patient variation in quality of life over 
time. Results indicated significant variation across individuals in both physical and mental 
quality of life. Regarding physical quality of life, three distinct classes of patients were 
identified. The majority of patients (i.e., 95%) reported stable physical health over time 
(classes 1 and 3). The largest class (class 1, 63%) reported quality of life that was 
significantly below population norms (i.e., approximately 1 SD). This group may reflect 
advances in transplantation that allow patients with greater comorbidity to be transplanted 
without subsequent declines in quality of life. A small fraction of patients (class 2) 
demonstrated average physical quality of life at baseline, then large decrements from 
baseline to 100 days-HCT, with no change thereafter. These patients were more likely to 
have had an allogeneic transplant, to have been hospitalized more days in the first 100 days 
post-HCT, and to report lower pre-HCT income compared to other patients. The only 
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baseline variables that were able to differentiate between these patients and those with 
average physical quality of life that remained stable (class 3) were income and transplant 
type. Early identification of patients at risk for poor outcomes remains an elusive research 
goal. Future research is needed to identify other measurable risk factors. An evolving 
understanding of the biology of transplant-related toxicity (e.g., GVHD) may point to new 
risk factors.
Regarding mental quality of life, four classes of patients were identified. The majority of 
patients (i.e., 91%) reported stable mental health over time. A minority of patients 
demonstrated change in mental quality of life; these patients reported average mental quality 
of life at baseline which improved at 100 days post-HCT and remained stable over time. 
Additionally, 16% of the sample reported poor mental quality of life that remained poor 
across time. Patients exhibiting low mental quality of life may benefit from early 
psychosocial intervention, as our data suggest that their mental health will not improve over 
time. Interestingly, almost half of the sample reported mental quality of life that was better 
on average than population norms at baseline and across time. Additional research is needed 
to determine the factors that contribute to their resiliency. For example, qualitative 
interviews with these individuals might yield valuable information that could be 
incorporated into future psychosocial interventions.
The stability of quality of life in most patients raises the possibility of response shift, or 
changes in patients’ internal standards of quality of life due to changes in their health status. 
For example, extreme changes in health status during the acute transplant period may affect 
how patients evaluate their quality of life, such that quality of life that was once considered 
very poor is now considered to be fair or good. Response shift in cancer patients has been 
well-documented (Andrykowski, et al 2009, Tierney, et al 2007) and may result in 
overestimation of quality of life. Future studies of quality of life in HCT should consider 
evaluating response shift (e.g., using structural equation modeling or the “then test”) (King-
Kallimanis, et al 2009, Schwartz and Sprangers 1999) to more accurately model quality of 
life. The stability of quality of life over time may also be due in part to the measure used; the 
SF-36 may be less sensitive to change than other measures of quality of life (e.g., the FACT-
BMT) (Lee, et al 2006), in part because transplant-related concerns are not represented.
Strengths of the current study include a large, multicenter sample of HCT recipients as well 
as the use of innovative statistical approaches and validated measures to characterize 
trajectories of patient quality of life. Study limitations should also be noted, however. 
Eligible patients were required to be in relatively good health (i.e., able to exercise). Patients 
who were unwilling to exercise (e.g., due to depression) may have declined study 
participation. In addition, the sample tended to be relatively homogenous in terms of race 
and ethnicity. Thus, results of the current study may not be generalizable to the larger 
population of HCT recipients, particularly those entering transplant with compromised 
physical function. Due to the sample size requirements of growth mixture modeling, it was 
not possible to run the models separately for autologous and allogeneic HCT recipients. 
Future studies with larger samples sizes should examine trajectories separately by transplant 
type. Of note, quality of life was not collected during the acute transplant period, so short-
term changes in quality of life may have been missed. In addition, quality of life was not 
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assessed after 180 days post-HCT, so the impacts of long-term and late effects were not 
characterized.
Results from the current study have high clinical relevance. First, results suggest that patient 
attrition only slightly biased estimates of quality of life. These findings provide more 
confidence in results from existing studies which have not taken attrition into account. In 
addition, findings suggest that while patients vary widely in terms of their quality of life in 
the first six months after transplant, large majorities of patients report physical and mental 
health at 100 days and 180 days post-HCT that is comparable to their baseline levels. This 
data can be used to better educate patients and caregivers regarding what to expect after 
HCT. Additional studies should examine trajectories of quality of life over a longer follow-
up period to characterize variability due to the impact of late effects among long-term 
survivors of HCT.
In summary, results from the current study suggest that reports of mean levels of quality of 
life among HCT recipients may mask significant inter-patient variability. These data are 
consistent with reports of patient heterogeneity regarding transplant-related morbidities and 
their effects on quality of life (Pidala, et al 2011). Results point to the importance of 
developing innovative strategies for analyzing and reporting quality of life data in HCT to 
provide clinical utility for providers, patients, and caregivers.
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Highlights
• This secondary analysis of the BMTCTN 0902 study examined the 
extent to which attrition results in biased estimates of patient quality of 
life and whether patients differ in terms of trajectories of quality of life 
in the first six months post-transplant.
• Results indicated that attrition resulted in slightly biased overestimates 
of quality of life but the amount of overestimation remained stable over 
time.
• Results also indicated that patients could be classified three distinct 
classes based on physical quality of life and four distinct classes based 
on mental quality of life.
• Taken together, these findings help to better understand the course of 
recovery after hematopoietic cell transplant.
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Figure 1. 
Mean SF-36 Physical Component Scores (PCS) and Mental Component Scores (MCS) cver 
Time by Study Completion Status. Error bars indicate standard errors.
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Figure 2. 
Growth Mixture Models Describing Trajectories of SF-36 Physical Quality of Life (A) and 
Mental Quality of Life (B).
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Table 1
Sociodemographic and Clinical Characteristics of the Sample (n=701).
Gender: n (%) female 302 (43)
Age: mean (SD) 54.5 (12.74)
Ethnicity: n (%) non-Hispanic 635 (91)
Race: n (%) White 608 (87)
Education: n (%) college graduate 556 (79)
Marital status: n (%) married 519 (74)
Annual household income: n (%) ≥ $75,000 200 (41%)
Diagnosis
 Aplastic anemia 9 (1)
 Acute leukemia 169 (24)
 Chronic leukemia 14 (2)
 Hodgkin’s lymphoma 48 (7)
 Myelodysplastic syndrome 59 (8)
 Myeloma 191 (27)
 Non-Hodgkin’s lymphoma 177 (25)
 Solid tumor 2 (<1)
 Other 31 (4)
 Missing 1 (<1)
Transplant type
 Autologous 354 (50)
 Allogeneic – myeloablative 175 (25)
 Allogeneic – non-myeloablative 172 (25)
Baseline Karnofsky score
 100 124 (18)
 90 283 (40)
 80 163 (23)
 ≤70 113 (16)
 Missing 18 (3)
Number of days hospitalized before day 100: mean (SD) 24.36 (15.73)
Attrition: n (%) not completing Time 3 assessment 219 (31)
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